Imugene share price surges 18% to lead the ASX 200 on Thursday

What’s behind the meteoric gain for this ASX 200 healthcare stock today?

| More on:
A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene was the best performer on the ASX 200 today. Its share price gained 20% and closed the session at 20 cents 
  • Imugene helped the ASX 200 healthcare sector outperform today – it was the only sector in the green at the closing bell 
  • Yesterday, Imugene released exciting news relating to the phase 1 clinical trial of its cancer-killing oncolytic virus 

The Imugene Limited (ASX: IMU) share price took off today despite the company’s silence.

However, today’s gains might have been a belated reaction to the news the company announced to the ASX yesterday.

As of Thursday’s close, the Imugene share price is 20 cents. That’s 17.65% higher than it was at the end of Wednesday’s session. It reached an intraday high of 21.5 cents today, representing a 26.47% gain.

For context, the S&P/ASX 200 Index (ASX: XJO) finished the day 1.6% lower.

Let’s take a closer look at the latest news from the clinical-stage immuno-oncology company.

Did this drive the Imugene share price today?

The Imugene share price leapt higher today as the healthcare sector outperformed.

In fact, the stock’s sector, represented by the S&P/ASX 200 Health Care Index (ASX: XHJ), was the only one in the green today. It closed 0.1% higher and was, perhaps unsurprisingly, led by Imugene.

The stock’s movement comes one day after the company announced the first patient has been dosed in its phase 1 clinical trial of its cancer-killing oncolytic virus CF33-hNIS, Vaxinia.

The trial is the first time the virus has come up against tumours in humans.

It has previously been shown to shrink colon, lung, breast, ovarian, and pancreatic cancer tumours in preclinical laboratory and animal models.

The study is being run in partnership with City of Hope. That’s the cancer treatment and research organisation that developed the virus. The study aims to recruit 100 patients across Australia and the United States.

The Imugene share price gained 3% yesterday. Though, the stock has notably underperformed throughout 2022 so far.

It is 53% lower than it was at the start of 2022. It has also fallen 50% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Healthcare Shares

What was the Sonic Healthcare share price when it first listed on the ASX?

Sonic Healthcare has an interesting history...

Read more »